Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation
NCT04132102Phase 4Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Nov 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of afatinib in squamous cell carcinoma of the lung (LSCC), sponsored by Shanghai Chest Hospital. Status: unknown.
02
Drugs
afatinib
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT04132102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04132102.